Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Adenocarcinoma × catumaxomab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 5 Carcinoma, Ovarian Epithelial 4 Peritoneal Neoplasms 3 Fallopian Tube Neoplasms 3 Stomach Neoplasms 2 Carcinoma 2 Neoplasms, Glandular and Epithelial 1 Neoplasms 1 Ascites 1 Adenocarcinoma 1

Interventions

Oxaliplatin 26 Gemcitabine 22 Fluorouracil 17 Capecitabine 16 Leucovorin 15 pembrolizumab 14 Docetaxel 13 Cisplatin 13 Bevacizumab 12 Radiotherapy 8 Paclitaxel 7 Irinotecan 7 Trastuzumab 6 Pemetrexed 6 Carboplatin 6 130-nm albumin-bound paclitaxel 6 durvalumab 5 cemiplimab 5 Sunitinib 4 Metformin 4 Gefitinib 4 Erlotinib Hydrochloride 4 trastuzumab deruxtecan 3 tislelizumab 3 cabozantinib 3 atezolizumab 3 Taxes 3 Sorafenib 3 Ramucirumab 3 Nivolumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01504256 2018-01-23

CatuNeo

AIO-Studien-gGmbH

Phase 2 Completed

Adenocarcinoma, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡